1. 1. Fallon M, Giusti R, Aielli F, et al. (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol, 29(4): p. iv166-iv191. [DOI:10.1093/annonc/mdy152]

2. Liang Q, Zhang K, Wang S, et al. (2020) Acupuncture for Cancer Pain - An Adjuvant Therapy for Cancer Pain Relief. Am J Chin Med, 48(8): 1769-1786. [DOI:10.1142/S0192415X20500883]

3. Eshaghi M (2020) The effect of pain management on pain reduction in women with breast cancer. sjmshm 2 (2): 1-5. [DOI:10.29252/sjmshm.2.2.1]

4. Li Y, Shu Y, Ji Q, et al. (2015) Attenuation of morphine analgesic tolerance by rosuvastatin in naïve and morphine tolerance rats. Inflammation, 38(1): 134-41. [DOI:10.1007/s10753-014-0015-y]

5. Wiffen PJ, Wee B, Derry S, et al. (2017) Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev, 7(7): p. Cd012592. [DOI:10.1002/14651858.CD012592]

6. Mercadante S, Arcuri E, Santoni A (2019) Opioid-Induced Tolerance and Hyperalgesia. CNS Drugs, 3(10): 943-955. [DOI:10.1007/s40263-019-00660-0]

7. Colvin LA, Bull F, Hales TG (2019) Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet, 393(10180): 1558-1568. [DOI:10.1016/S0140-6736(19)30430-1]

8. Jiang W, Hu JW, He XR, et al. (2021) Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res, 40(1): 241. [DOI:10.1186/s13046-021-02041-2]

9. Beckwitt CH, Clark AM, Ma B, et al. (2018) Statins attenuate outgrowth of breast cancer metastases. Br J Cancer, 119(9): 1094-1105. [DOI:10.1038/s41416-018-0267-7]

10. Santoni M, Monteiro FSM, Massari F, et al. (2022) Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol Hematol, 176: 103731. [DOI:10.1016/j.critrevonc.2022.103731]

11. Sato T, Arakawa M, Tashima Y, et al. (2018) Statins Reduce thoracic aortic aneurysm growth in marfan syndrome mice via inhibition of the ras-induced ERK (Extracellular Signal-Regulated Kinase) signaling pathway. J Am Heart Assoc, 7(21): e008543. [DOI:10.1161/JAHA.118.008543]

12. Tsubaki M, Takeda T, Sakamoto K, et al. (2015) Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways. Am J Cancer Res, 5(1): 168-79.

13. Xu X, Gao W, S Cheng, et al. (2017) Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflammation, 14(1): 167. [DOI:10.1186/s12974-017-0934-2]

14. Pathak NN, Balaganur V, Lingaraju MC, et al. (2014) Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Neurochem Int, 68: 1-9. [DOI:10.1016/j.neuint.2014.01.014]

15. Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health. Accessed April 2021. [cited 2017 November 27]; Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

16. Gillon JT, Smith SE, Lowden MR (2013) Atorvastatin as novel treatment for neuropathic pain: a case report. Clin J Pain, 29(12): e46-8. [DOI:10.1097/AJP.0b013e3182a03c2e]

17. Pathak NN, Balaganur V, Lingaraju MC, et al. (2015) Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy. Pharmacol Rep, 67(3): 513-9. [DOI:10.1016/j.pharep.2014.12.005]

18. Corli O, Santucci C, Corsi N, et al. (2019) The Burden of Opioid Adverse Events and the Influence on Cancer Patients' Symptomatology. J Pain Symptom Manage, 57(5): 899-908.e6. [DOI:10.1016/j.jpainsymman.2019.02.009]